Viral Antigen Ingredients TRIZ Cases

Chemically synthesized DNA fragments and leporipox recombination enable modified poxviruses with lower toxicity while retaining protection.

Antibody-heavy-chain RICs fused to HSV2 glycoprotein D boost titers and cross-neutralization without adjuvant.

PCR, antibody titers, and immune markers support targeted quarantine and vaccination decisions during EHV-1 outbreaks.

Polyalkyleneimine polyplexes support stable, efficient intramuscular RNA delivery.

Mutant papillomavirus L1 capsids carry antigen peptides, bind tumor proteoglycans, and redirect preexisting immunity against cancer cells.

Specific immunogenic peptides stimulate CD8+ T cell responses to inhibit viral loads and improve survival rates in HSV infection models.

Processed cell therapies combine primed T cells and mesenchymal stem cells to reduce cancer recurrence, viral infections, and graft versus host disease.

Site-specific phosphorylation creates stable antigen-adjuvant complexes that enhance humoral immunity while reducing adverse reactions.

Optimized recombinant HIV envelope proteins with specific amino acid mutations improve trimer formation and stability.

Lentiviral vectors use minimal promoters to drive HTLV-1 fusion protein expression in antigen-presenting cells.

MVA vector expressing membrane-bound HIV envelope protein boosts antibody responses to viral targets.

Recombinant baculovirus-expressed ORF-2 antigen combined with adjuvants forms an immunogenic composition.

Engineered gp120 inner domain immunogens stabilize C1/C2 epitopes in CD4-bound state, overcoming poor immunogenicity of conventional vaccines.

Sequential micro-dosing of sterile vaccine to ocular mucosa eliminates injection site irritation and technician dependency.

Modifying the FAdV fiber gene L1 loop creates attenuated strains that reduce mortality while maintaining safety.

Immunogenic compositions substitute hypervariable residues with conserved amino acids to elicit broad immune responses across multiple influenza strains.

Positively charged amino acids stabilize viral antigens in pharmaceutical compositions.

Hydrocarbon staples lock gp41 peptides into stable helical structures, preventing proteolytic degradation and enabling broadly neutralizing antibody generation.

Aluminum and CpG ODN adjuvants in recombinant HPV vaccines improve immunogenicity while reducing required doses.

Stabilizing the C5 domain of gp120 with gp41 via peptide constructs blocks chronic immune stimulation, addressing ineffective HIV treatment approaches.

Substituting segments in the HPV51 L1 protein creates a universal virus-like particle that provides broad cross-protection against HPV51, HPV69, and HPV26.

Conjugate compounds combine modified preS peptides with bile acids to block NTCP receptors, preventing HBV and HDV entry into liver cells.

Engineered red blood cells express specific rare antigen phenotypes to simplify antibody identification and reduce testing complexity.

Deleting B8R and B19R genes in vaccinia vectors resolves the safety versus immunogenicity trade-off.

Segmenting L1 prophylaxis with E7 therapeutic antigens eradicates pre-infected cells while maintaining vaccine simplicity.

Recombinant synthetic capsid proteins overcome low viral titers to deliver potent immune protection against PCV2.

Treating Madin-Darby bovine kidney cell medium via cold atmospheric plasma boosts viral yields, addressing low efficiency and high costs in vaccine production.

Segmented polypeptides combined with adjuvants enhance immune response to reduce herpes simplex virus type 2 symptoms and recurrence.

Segmented HBV long peptides target conserved replication regions to overcome poor genotype coverage and limited HLA binding.

Extracting CD8+ T cells from allogeneic infusions reduces graft-versus-host disease while modified CD4+ cells induce tumor regression.

Combining rotavirus strains CDC-9 and CDC-66 resolves the contradiction between strong G1 protection and lack of cross-protection against diverse serotypes.

Pre-binding terminal protein to inverted repeat DNA reduces contamination and production time for high-titer gutless vectors.

Vpx-containing lentiviral vectors with highly mannosylated alphavirus glycoproteins enhance transduction efficiency for non-dividing dendritic cells.

A recombinant lumpy skin disease virus knock-out mutant lacking the interleukin-10-like gene induces robust immune responses in livestock.

SYBR green real-time PCR assays quantify viral load by targeting conserved genomic regions, overcoming false negatives from high genetic variability.

Two-stage vaccination with optimized cryptic peptides followed by native peptides maintains immune response while avoiding autoimmunity.

Neutralizing antibodies prevent severe morbidity in immunocompromised patients by intercepting viral entry before cellular infection occurs.

Combining genotype 1 and 4 antigens in one vaccine resolves the trade-off between specific efficacy and broad-spectrum protection against virulent strains.

Recombinant viral vectors insert transgenes into the Marek's disease genome to create a single vaccine platform.

Agroinfiltration in plant cells produces HPV pseudovirions, replacing expensive mammalian cultures to lower vaccine testing costs.

Segmenting the VP4 protein into soluble domains reduces production costs while maintaining immunogenicity against diverse serotypes.

Truncated HPV33 L1 protein self-assembles into virus-like particles, enabling high-yield production in E. coli to overcome low expression levels.

Deleting latency genes from recombinant HSV vectors prevents viral reactivation while maintaining replication for sterile immunity.

Mutated HPV11 L1 protein induces neutralizing antibodies against multiple HPV types through chimeric self-assembly.

Wild-type JC polyomavirus VP1 polypeptide composition elicits broadly cross-neutralizing antibody responses against multiple viral genotypes.

A subunit vaccine uses three ASFV polypeptides to induce reliable protection against African swine fever challenge in pigs.

Deleting the I177L gene from African Swine Fever Virus creates a live attenuated vaccine that induces protective immunity in swine.

Segmented recombinant VP2 and VP5 proteins eliminate whole-virus production time while enabling DIVA compatibility across multiple serotypes.

Mutated HPV39 L1 protein induces high-titer neutralizing antibodies against multiple human papillomavirus types through segment substitution.